Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Novartis
Eli Lilly and Company
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Montefiore Medical Center
Tango Therapeutics, Inc.
Hoosier Cancer Research Network
Actuate Therapeutics Inc.
NRG Oncology
NRG Oncology
NRG Oncology
Mayo Clinic
Institut Cancerologie de l'Ouest
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
Avera McKennan Hospital & University Health Center
Brigham and Women's Hospital
RasCal Therapeutics, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Filamon LTD
University Hospital Heidelberg
UMC Utrecht
M.D. Anderson Cancer Center
Thomas Jefferson University
Shanghai Chest Hospital
University of California, Davis
Essen Biotech
Memorial Sloan Kettering Cancer Center
Second Affiliated Hospital of Nanchang University
University of Nebraska
Adela, Inc
Eli Lilly and Company
M.D. Anderson Cancer Center
Dysplasia Diagnostics Limited
Var2 Pharmaceuticals
Harvard Medical School (HMS and HSDM)
Stanford University
Mayo Clinic
University of Washington
Black Diamond Therapeutics, Inc.
City of Hope Medical Center
Degron Therapeutics Co.
University Health Network, Toronto
National Cancer Institute (NCI)
Sun Yat-sen University
Dana-Farber Cancer Institute
University of Kentucky
Massive Bio, Inc.